Journal of Diabetes Investigation (Sep 2021)

Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials

  • Mitsuhisa Komatsu,
  • Hirotaka Watada,
  • Shizuka Kaneko,
  • Bue F Ross Agner,
  • Tomoyuki Nishida,
  • Kohei Kaku

DOI
https://doi.org/10.1111/jdi.13525
Journal volume & issue
Vol. 12, no. 9
pp. 1610 – 1618

Abstract

Read online

Abstract Aims/Introduction To assess efficacy and safety of insulin degludec/liraglutide (IDegLira) in Japanese participants with type 2 diabetes across different baseline characteristics. Materials and Methods Data from two randomized controlled trials were used: DUAL I Japan (n = 819 insulin‐naïve participants) and DUAL II Japan (n = 210 insulin‐experienced participants). Outcomes were assessed according to baseline glycated hemoglobin ( HbA1c; 65 years in DUAL II Japan. Conclusions IDegLira reduced HbA1c in Japanese participants with type 2 diabetes across baseline HbA1c, body mass index and age categories, without unexpected safety issues.

Keywords